-
1
New CRISPR method addresses CAR T cell manufacturing bottlenecks.
-
2
Two-vector system combines CRISPR-Cas9 and AAV.
-
3
Enables in vivo gene insertion into T cells.
-
4
Effective in humanized mouse models.
-
5
CAR T cells demonstrate high anti-tumor activity.
-
6
B cell depletion is a key biological effect.
-
7
Potential to lower costs and improve access to CAR T therapies.
Original Source(s)
Related Content
AI As Collaborator in Cancer Research and in Clinical Care
Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identif...
by Jo Cavallo
March 30, 2026
-
10 min
Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment
In a Chinese study reported in the Journal of Clinical Oncology, Huang et al developed a classification for metabolic subtypes of nasopharyngeal carcinoma that may help identify patients benefiting mo...
March 30, 2026
-
3 min
Diagnostics Explores the Fragmentome
An AI-augmented blood test detects early liver fibrosis and other diseases
March 30, 2026
-
5 min
